![Fred Grossman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fred Grossman
Präsident bei
COYA THERAPEUTICS, INC.
Vermögen: 13 062 $ am 31.05.2026
Profil
Dr. Fred Grossman is a President & Chief Medical Officer at Coya Therapeutics, Inc. Dr. Grossman was previously employed as a Chief Medical Officer by Empyrean Neuroscience, Inc., a Chief Medical Officer by Mesoblast Ltd., a Chief Medical Officer by Mesoblast, Inc., a President & Chief Medical Officer by Glenmark Pharmaceuticals Ltd., a President & Chief Medical Officer by Glenmark Pharmaceuticals Inc., USA, a Head-Clinical Development & Medical Affairs by Sunovion Pharmaceuticals, Inc., and a Global Head-Medical Affairs Organization by Bristol Myers Squibb Co. He also served on the board at Reunion Neuroscience, Inc. He received his undergraduate degree from Hahnemann University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 01.05.2026 | 2’710 ( 0.01% ) | 13 062 $ | 31.05.2026 |
Aktive Positionen von Fred Grossman
| Unternehmen | Position | Beginn |
|---|---|---|
| COYA THERAPEUTICS, INC. | Präsident | 17.07.2023 |
Ehemalige bekannte Positionen von Fred Grossman
| Unternehmen | Position | Ende |
|---|---|---|
Empyrean Neuroscience, Inc.
 Empyrean Neuroscience, Inc. Pharmaceuticals: OtherHealth Technology Engages in genetic engineering of fungi and plants to create neuroactive therapeutics | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2023 |
| MESOBLAST LIMITED | Technik-/Wissenschafts-/F&E-Leiter | 02.02.2022 |
| GLENMARK PHARMACEUTICALS LIMITED | Präsident | 01.01.2019 |
Glenmark Pharmaceuticals Inc., USA
 Glenmark Pharmaceuticals Inc., USA Pharmaceuticals: MajorHealth Technology Manufactures and distributes generic pharmaceutical products | Präsident | 01.08.2018 |
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals for oncology, CNS, urology and rare diseases | Corporate Officer/Principal | 01.10.2015 |
Ausbildung von Fred Grossman
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
79
Beziehungen ersten Grades
10
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals for oncology, CNS, urology and rare diseases | Health Technology |
Mesoblast, Inc.
 Mesoblast, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes biopharmaceutical products | Health Technology |
Glenmark Pharmaceuticals Ltd.
 Glenmark Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceuticals | Health Technology |
Mesoblast Ltd.
 Mesoblast Ltd. BiotechnologyHealth Technology Engages in the development and commercialization of biological and adult stem cells products | Health Technology |
Hahnemann University
 Hahnemann University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Glenmark Pharmaceuticals Inc., USA
Glenmark Pharmaceuticals Inc., USA Pharmaceuticals: MajorHealth Technology Manufactures and distributes generic pharmaceutical products | Health Technology |
Coya Therapeutics, Inc.
 Coya Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that focuses on research and development of therapies to enhance the function of regulatory T cells | Health Technology |
Empyrean Neuroscience, Inc.
Empyrean Neuroscience, Inc. Pharmaceuticals: OtherHealth Technology Engages in genetic engineering of fungi and plants to create neuroactive therapeutics | Health Technology |
Reunion Neuroscience, Inc.
 Reunion Neuroscience, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops FDA-approved serotonergic psychedelic therapeutic solutions for underserved mental health disorders | Health Technology |
